Stratview Research delivers key insights into the global Ophthalmic Pharmaceutical Drugs Market. According to Stratview Research, the market is segmented By Type (Prescription Drugs, OTC Drugs), By Class (Antiallergy, Anti-VEGF Agents, Anti-inflammatory [Nonsteroidal Drugs, Steroidal Drugs], Antiglaucoma, Others), By Disease (Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Retinal Disorders [Macular Degeneration, Diabetic Retinopathy, Others], Uveitis, Others), By Dosage (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments), and Region - COVID-19 Impact Analysis and Forecast to 2028.
Why invest in this report?
The report provides an in-depth analysis of the Ophthalmic Pharmaceutical Drugs Market including critical market information and valuable insights which are of high value to the companies, enabling them to know and understand several other opportunities in the market. The report also aims at answering the following key questions –
To get detailed insights about this study, click here: https://www.stratviewresearch.com/Request-Sample/2285/Ophthalmic-Pharmaceutical-Drugs-Market.html#form
Key Players:
Key players operating in the ophthalmic pharmaceutical drugs market are-
Segment Analysis
By Type
The market has been segmented into (Prescription Drugs, and OTC Drugs). The Prescription Drugs segment accounted for a revenue share of nearly 60% in 2021.
By Class Type
The ophthalmic pharmaceutical drugs market is classified into antiallergy, anti-VEGF agents, anti-inflammatory antiglaucoma, and others. The Anti-VEGF Agents segment accounted for a revenue share of more than 31.0% in 2021 and is estimated to register a healthy CAGR during the forecast timeline. This is mainly attributed to the growing adoption rate and large presence of global industry players with extensive product portfolios. The segment growth is propelled by robust commercial performances of Avastin (bevacizumab), Lucentis (ranibizumab), and Macugen (pegaptanib), which bolsters the segment growth.
By Disease Type
The market has been segmented into (Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Retinal Disorders [Macular Degeneration, Diabetic Retinopathy, and Others], Uveitis, and Others). The Retinal Disorders segment accounted for a revenue share of more than 33.0% in 2021.
By Dosage Type
The market has been segmented into (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments). The Eye Drops segment accounted for a revenue share of more than 34.0% in 2021.
By Region
The North American market accounted for a revenue share of more than 39.5% in 2021 and is expected to grow at a substantial CAGR in the following years. This is mainly ascribed to a surge in the number of cataract surgeries performed, high consumer awareness, the presence of excellent healthcare infrastructure, the large presence of a majority of major players, and a rise in government intervention for the prevention of visual impairment, thereby proliferating the regional market growth.
Competitive Benchmarking
Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.
Share your requirements at -
Stratview Research
E-mail: [email protected]
Direct: +1-313-307-4176
About Stratview Research:
Stratview Research is a credible source for gaining market intelligence to exponentially accelerate the user’s business. Our team of veterans and analysts have extensive experience in executing custom research projects for mid-sized to fortune companies, in the areas of Market Assessment, Opportunity Screening, Competitive Intelligence, Due Diligence, Target Screening, Market Entry Strategy, and more.
